Health AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline January 17, 2024 177 TelecomApril 3, 2026Democrat rips Polymarket for taking bets on fate of US pilot shot down over Iran TelecomApril 3, 2026A third of Americans planning to invest in high-risk, speculative assets: Study TelecomApril 3, 2026Anthropic launches new corporate PAC to ramp up election spending TelecomApril 3, 2026FBI labels data breach ‘major incident,’ notifies Congress TelecomApril 3, 2026Palantir-linked campaign donations put Democrats in tight spot AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight. Prime Plus Facebook Twitter Pinterest WhatsApp SportsApril 4, 2026Proposed Trade Sees Knicks Flip All-Star For Giannis Antetokounmpo Sports Warriors’ Steph Curry Sends Strong Message to Victor Wembanyama April 4, 2026 Sports Giants Get Brutal José Butto News April 4, 2026 Sports IPL Live: Who Will Win Today’s MI vs DC Match? 3rd Wicket Falls April 4, 2026
